Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is believed to play important roles in different diseases by binding to its specific receptor suppression of tumorigenicity 2 (ST2). In the heart, IL-33 is expressed in different cells including cardiomyocytes, fibroblasts, endothelium, and epithelium. Although many studies have been devoted to investigating the effects of IL-33 on heart diseases, its roles in myocardial injuries remain obscure, and thus further studies are mandatory to unravel the underlying molecular mechanisms. We highlighted the current knowledge of the molecular and cellular characteristics of IL-33 and then summarized its major roles in different myocardial injuries, mainly focusing on infection, heart transplantation, coronary atherosclerosis, myocardial infarction, and diabetic cardiomyopathy. This narrative review will summarize current understanding and insights regarding the implications of IL-33 in cardiac diseases and its diagnostic and therapeutic potential for cardiac disease management.
ZhangCWangWHeWXiNWangYLiuL. Dynamic model for characterizing contractile behaviors and mechanical properties of a cardiomyocyte.Biophys J2018;114:188–200
2.
SavvoulidisPButlerJKalogeropoulosA. Cardiomyopathy and heart failure in patients with HIV infection.Can J Cardiol2019;35:299–309
3.
KimAHJangJEHanJ. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy.Biomed Pharmacother2022;145:112463
4.
NaritaKAmiyaE. Social and environmental risks as contributors to the clinical course of heart failure.Heart Fail Rev2022;27:1001–16
5.
DwyerGKD’CruzLMTurnquistHR. Emerging functions of IL-33 in homeostasis and immunity.Annu Rev Immunol2022;40:15–43
6.
Bou SabaJTurnquistHR. The reparative roles of IL-33.Transplantation2023;107:1069–78
7.
DemyanetsSKaunCPentzRKrychtiukKARauscherSPfaffenbergerSZuckermannAAliabadiAGrogerMMaurerGHuberKWojtaJ. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.J Mol Cell Cardiol2013;60:16–26
8.
BaekkevoldESRoussignéMYamanakaTJohansenF-EJahnsenFLAmalricFBrandtzaegPErardMHaraldsenGGirardJ-P. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules.Am J Pathol2003;163:69–79
9.
SchmitzJOwyangAOldhamESongYMurphyEMcClanahanTKZurawskiGMoshrefiMQinJLiXGormanDMBazanJFKasteleinRA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.Immunity2005;23:479–90
10.
CarriereVRousselLOrtegaNLacorreD-AAmerichLAguilarLBoucheGGirardJ-P. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.Proc Natl Acad Sci U S A2007;104:282–7
11.
CayrolCGirardJ-P. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family.Immunol Rev2018;281:154–68
12.
LiuXHammelMHeYTainerJAJengUSZhangLWangSWangX. Structural insights into the interaction of IL-33 with its receptors.Proc Natl Acad Sci U S A2013;110:14918–23
13.
MoussionCOrtegaNGirardJP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?PLoS One2008;3:e3331
14.
HatzioannouABanosASakelaropoulosTFedonidisCVidaliMSKohneMHandlerKBoonLHenriquesAKoliarakiVGeorgiadisPZoidakisJTermentziABeyerMChavakisTBoumpasDTsirigosAVerginisP. An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion.Nat Immunol2020;21:75–85
15.
WangZShiLHuaSQiCFangM. IL-33 ameliorates experimental colitis involving regulation of autophagy of macrophages in mice.Cell Biosci2019;9:10
16.
LegereSAHaidlIDLegareJFMarshallJS. Mast cells in cardiac fibrosis: new insights suggest opportunities for intervention.Front Immunol2019;10:580
17.
HeYHwangSAhmedYAFengDLiNRibeiroMLafdilFKisselevaTSzaboGGaoB. Immunopathobiology and therapeutic targets related to cytokines in liver diseases.Cell Mol Immunol2021;18:18–37
18.
YangJHuangXHuFFuXJiangZChenK. LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2.Cell Cycle2019;18:3393–403
19.
TraversJRochmanMMiracleCEHabelJEBrusilovskyMCaldwellJMRymerJKRothenbergME. Chromatin regulates IL-33 release and extracellular cytokine activity.Nat Commun2018;9:3244
20.
MarviePLisbonneML’Helgoualc’hARauchMTurlinBPreisserLBourd-BoittinKThéretNGascanHPiquet-PellorceCSamsonM. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans.J Cell Mol Med2010;14:1726–39
21.
NishidaAAndohAImaedaHInatomiOShiomiHFujiyamaY. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts.Gut2010;59:531–41
22.
RamezaniFBabaieFAslaniSHemmatzadehMMohammadiFSGowhari-ShabgahAJadidi-NiaraghFEzzatifarFMohammadiH. The role of the IL-33/ST2 immune pathway in autoimmunity: new insights and perspectives.Immunol Invest2022;51:1060–86
23.
TominagaS. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor.FEBS Lett1989;258:301–4
24.
LarsenKMMinayaMKVaishVPeñaMMO. The role of IL-33/ST2 pathway in tumorigenesis.Int J Mol Sci2018;19:2676
25.
GriesenauerBPaczesnyS. The ST2/IL-33 axis in immune cells during inflammatory diseases.Front Immunol2017;8:475
26.
MoritzDRRodewaldHRGheyselinckJKlemenzR. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors.J Immunol1998;161:4866–74
27.
MattaBMLottJMMathewsLRLiuQRosboroughBRBlazarBRTurnquistHR. IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2(+) regulatory T cells.J Immunol2014;193:4010–20
28.
DinarelloCA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor.Immunity2005;23:461–2
29.
PuscedduIDieplingerBMuellerT. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.Clin Chim Acta2019;495:493–500
MarinoLConcistreASuppaMGalardoGRosaABertazzoniGPuglieseFLetiziaCPetramalaL. Prognostic role of sST2 in acute heart failure and COVID—19 infection—a narrative review on pathophysiology and clinical prospective.Int J Mol Sci2022;23:8230
32.
EkenÖKafkasME. Effects of low and high intensity interval training exercises on VO2max and components of neuromuscular and vascular system in male volunteers.J Musculoskelet Neuronal Interact2022;22:352–63
33.
WangCDongCSXiongSD. IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis.J Mol Cell Cardiol2017;103:22–30
34.
AbstonEDCoronadoMJBucekABedjaDShinJKimJBKimEGabrielsonKLGeorgakopoulosDMitznerWFairweatherD. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease.Clin Dev Immunol2012;2012:129486
35.
CorstenMFSchroenBHeymansS. Inflammation in viral myocarditis: friend or foe?Trends Mol Med2012;18:426–37
36.
MihatschKNestlerMSaluzHPHenkeAMunderT. Proapoptotic protein Siva binds to the muscle protein telethonin in cardiomyocytes during coxsackieviral infection.Cardiovasc Res2009;81:108–15
37.
GuiJChenRXuWXiongS. Remission of CVB3-induced myocarditis with Astragaloside IV treatment requires A20 (TNFAIP3) up-regulation.J Cell Mol Med2015;19:850–64
38.
ChengXLiaoYHGeHXLiBZhangJYYuanJWangMLiuYGuoZQChenJZhangJZhangLJ. Th1/Th2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation.J Clin Immunol2005;25:246–53
39.
LiuWLiJNTianWDXuTFZhangZY. Chronic alcohol consumption induces cardiac remodeling in mice from Th1 or Th2 background.Exp Mol Pathol2011;91:761–7
40.
TrialJACieslikKAHaudekSBDuerrschmidCEntmanML. Th1/M1 conversion toTh2/M2 responses in models of inflammation lacking cell death stimulates maturation of monocyte precursors to fibroblasts.Front Immunol2013;4:287
41.
YinHLiXYJinXBZhangBBGongQYangHZhengFGongFLZhuJY. IL-33 Prolongs murine cardiac allograft survival through induction of TH2-type immune deviation.Transplantation2010;89:1189–97
42.
LiTFZhangZQBartolacciJGDwyerGKLiuQMathewsLRVelayuthamMRoessingASLeeYCDaiHLShivaSOberbarnscheidtMHDzikiJLMulletSJWendellSGWilkinsonJDWebberSAWood-TrageserMWatkinsSCDemetrisAJHusseyGSBadylakSFTurnquistHR. Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection.J Clin Invest2020;130:5397–412
43.
BrunnerSMSchiechlGFalkWSchlittHJGeisslerEKFichtner-FeiglS. Interleukin-33 prolongs allograft survival during chronic cardiac rejection.Transpl Int2011;24:1027–39
44.
SimeonovicCJTownsendMJKarupiahGWilsonJDZarbJCMannDAYoungIG. Analysis of the Th1/Th2 paradigm in transplantation: interferon-gamma deficiency converts Th1-type proislet allograft rejection to a Th2-type xenograft-like response.Cell Transplant1999;8:365–73
45.
Poole-WilsonPA. Implications of recent heart failure trials for patients with hypertension.Curr Cardiol Rep2001;3:504–10
46.
SanadaSHakunoDHigginsLJSchreiterERMcKenzieANLeeRT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.J Clin Invest2007;117:1538–49
YuanYLiPYeJ. Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis.Protein Cell2012;3:173–81
49.
ZhangHFWuMXLinYQXieSLHuangTCLiuPMNieRQMengQQLuoNSChenYXWangJF. IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation.Exp Mol Med2017;49:e388
MillerAMXuDAsquithDLDenbyLLiYBSattarNBakerAHMcInnesIBLiewFY. IL-33 reduces the development of atherosclerosis.J Exp Med2008;205:339–46
52.
AimoAMiglioriniPVergaroGFranziniMPassinoCMaiselAEmdinM. The IL-33/ST2 pathway, inflammation and atherosclerosis: trigger and target?Int J Cardiol2018;267:188–92
53.
DemyanetsSTentzerisIJaraiRKatsarosKMFarhanSWonnerthAWeissTWWojtaJSpeidlWSHuberK. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis.Cytokine2014;67:65–70
54.
DemyanetsSSpeidlWSTentzerisIJaraiRKatsarosKMFarhanSKrychtiukKAWonnerthAWeissTWHuberKWojtaJ. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome.PLoS One2014;9:e95055
55.
WangYPWangJHWangXLLiuJYJiangFYHuangXLHangJYQinWMaSXZhangJYuanMJLiJBLuZGWeiM. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention.J Cell Mol Med2017;21:2677–84
56.
LiuCLShenDLZhuKTangJNWangXFZhangLZhangJY. Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease.Coronary Artery Dis2014;25:498–504
57.
ShimpoMMorrowDAWeinbergEOSabatineMSMurphySAAntmanEMLeeRT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.Circulation2004;109:2186–90
58.
WeinbergEOShimpoMHurwitzSTominagaSRouleauJLLeeRT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker.Circulation2003;107:721–6
59.
GhaliRHabeichiNJKaplanATannousCAbidiEBekdashAFarhatRItaniHJurjusABoozGWMallatZZoueinFA. IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture.Clin Sci2020;134:1191–218
60.
XingJLiuJGengT. Predictive values of sST2 and IL-33 for heart failure in patients with acute myocardial infarction.Exp Biol Med2021;246:2480–6
61.
XiaJGQuYYinCLXuD. Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction.Cardiol J2017;24:188–94
62.
ChenBGengJGaoSXYueWWLiuQ. Eplerenone modulates interleukin-33/sST2 signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction.J Interferon Cytokine Res2018;38:137–44
63.
TanYZhangZZhengCWintergerstKAKellerBBCaiL. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence.Nat Rev Cardiol2020;17:585–607
64.
ShkodaARuizPADanielHKimSCRoglerGSartorRBHallerD. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation.Gastroenterology2007;132:190–207
65.
LiuXXuQWangXZhaoZZhangLZhongLLiLKangWZhangYGeZ. Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model.Pharmacol Res2015;93:43–51
66.
WuMXWangSHXieYChenZTGuoQYuanWLGuanCXuCZHuangYNWangJFZhangHFChenYX. Interleukin-33 alleviates diabetic cardiomyopathy through regulation of endoplasmic reticulum stress and autophagy via insulin-like growth factor-binding protein 3.J Cell Physiol2021;236:4403–19
67.
RuiTZhangJXuXYaoYKaoRMartinCM. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus.Cardiovasc Res2012;94:370–8
68.
FousterisEMelidonisAPanoutsopoulosGTzirogiannisKFoussasSTheodosis-GeorgilasATzerefosSMatsagosSBoutatiEEconomopoulosTDimitriadisGRaptisS. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction.Cardiovasc Diabetol2011;10:101
69.
JhaDGoenkaLRamamoorthyTSharmaMDhandapaniVEGeorgeM. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes.Eur J Clin Invest2018;48:e12994
70.
AmbariAMSetiantoBSantosoARadiBDwiputraBSusilowatiETulrahmiFDoevendansPACramerMJ. Angiotensin converting enzyme inhibitors (ACEIs) decrease the progression of cardiac fibrosis in rheumatic heart disease through the inhibition of IL-33/sST2.Front Cardiovasc Med2020;7:115
71.
JanuzziJLMebazaaADi SommaS. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel.Am J Cardiol2015;115:26B–31B
72.
RuiTTangQ. IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKCβ/JNK Pathway.PLoS One2013;8:e56089
73.
IannazzoFPellicanoCColalilloARamacciniCRomanielloAGiganteARosatoE. Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement.Clin Exp Med2023;23:897–903
74.
PellicanoCIannazzoFRomaggioliLRosatoE. IL33 and sST2 serum level in systemic sclerosis microvascular involvement.Microvasc Res2022;142:104344
75.
RaccaVTorriAGratiPPanzarinoCMarventanoISaresellaMCastiglioniP. Inflammatory cytokines during cardiac rehabilitation after heart surgery and their association to postoperative atrial fibrillation.Sci Rep2020;10:8618
76.
OpincASarnikJBrzezinskaOMakowskiMLewandowska-PolakAMakowskaJ. Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study.Rheumatol Int2020;40:1133–41
